Navigation Links
Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
Date:7/31/2012

ticals Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's lead proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal (GI) hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in chronic idiopathic constipation (CIC) patients. In October, 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide to treat CIC. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome (IBS-C), with the first trial in IBS-C patients planned for the second half of 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.

About Plecanatide

Plecanatide is a member of a new class of essentially non-systemic drugs, referred to as guanylate cyclase C (GC-C) agonists, that are currently in development to treat CIC and IBS-C. Plecanatide is a synthetic analog of uroguanylin, a natriuretic hormone that regulates ion and fluid transport in the GI tract. Orally-administered plecanatide binds to and activates GC-C receptors expressed on epithelial cells lining the GI mucosa, resulting in activation of the cystic fibrosis transmembrane conductance regulator (CFTR), and leading to augmented flow of chloride and water into the lumen of the gut. Activation of the GC-C receptor pathway is believed to facilitate bowel movement as well as producing other beneficial physiological responses including improvement in abdominal pain and inflammation. In animal models, oral administration of plecanatide promotes intestinal secretion and also ameliorates GI
'/>"/>

SOURCE Synergy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
5. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
6. Icahn Issues Statement Regarding Amylin Pharmaceuticals
7. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
8. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
9. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
10. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
11. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very pleased ... as its new Chief Executive Officer.  Mark was promoted ... he has overseen the company,s four facilities in ... Rica.  Mr. King joined Tegra Medical in 2012 with 20+ ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Surgical Information Systems ("SIS"), a leader in ... Health System has extended its enterprise agreement with ... solution. The implementation will start at North Shore University ... Health Systems hospitals. (Logo:   http://photos.prnewswire.com/prnh/20080722/SISLOGO ...
... 2011 Mitsubishi Chemical Medience Corporation announced today ... has granted 510(k) premarketing notification clearance to the ... the way for its sale in the United ... with the PATHFAST analysis system, a unique, self-contained, ...
Cached Medicine Technology:North Shore-LIJ Health System Selects SIS Anesthesia 2North Shore-LIJ Health System Selects SIS Anesthesia 3North Shore-LIJ Health System Selects SIS Anesthesia 4Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 2Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 3
(Date:4/24/2014)... The University of Manchester have identified a way to ... open to treatment. , The study published today in ... the development of drugs to target cells that have ... the discovery whilst exploring the possible mechanisms behind resistance ... breast and colon cancer. , Dr Andrew Gilmore, who ...
(Date:4/24/2014)... April 24, 2014 Scientific research at UT ... heart can heal itself completely, whereas the adult heart ... today has revealed why the heart loses its incredible ... simple oxygen. , Yes, oxygen. It is ... to circulate oxygen-rich blood throughout the body. But at ...
(Date:4/24/2014)... lenses coated with an antimicrobial peptide could help to lower ... Optometry and Vision Science , official journal ... journal is published by Lippincott Williams & Wilkins , ... in animals and now humans support the biocompatibility and safety ... the new research by Debarun Dutta, B.Optom, of The University ...
(Date:4/24/2014)... Changes in managing patients before, during and after ... reduced readmission rates, according to researchers who led a ... The practice, called enhanced recovery, is easier on patients ... bowel evacuation that are typically prescribed. After surgery, patients ... as possible, leading to faster recoveries. , Among findings ...
(Date:4/24/2014)... a professor in the new Institute for Biomedical ... five-year, $2.83 million federal grant to develop novel ... The grant from the Eunice Kennedy Shriver National ... the National Institutes of Health will support Plemper,s ... and at least one distinct alternative compound. , ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Oxygen diminishes the heart's ability to regenerate, researchers discover 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:New approach for surgery patients cuts hospital stays and costs 2Health News:New approach for surgery patients cuts hospital stays and costs 3
... outlines key financial concerns, including Social Security disability, for ... Conference in Atlanta. , ... ... The diagnosis of a long-term degenerative disease like ...
... the Award Winning ... CytoViva Nano-scale Microscope, ... provider,of optical imaging solutions to the nano-technology research market, ... scale microscope system. This combination of technologies enables,scientists to ...
... Cleveland Clinic ... Expertise Anywhere in the World, CLEVELAND, Aug. 21 ... provides specialized care by,Cleveland Clinic physicians, nurse practitioners and critical ... intensive,care unit, helicopter and fixed-wing jets., With the launch ...
... 21 Bruce Bodaken,Chairman, President & CEO of Blue ... 2008 Rocky Mountain Roundtable on Health, Wellness and,Prevention at ... 25, 2008, 9:30 a.m. MDT at Boettcher Hall in ... importance of wellness programs,in health reform, and the ways ...
... Fairview and,Blue Cross and Blue Shield of Minnesota ... clinics to remain as participating providers,in all of Blue ... expire at midnight on Friday, August 22, 2008. Agreement ... participating network,hospitals with the Blue Cross network. The hospital ...
... It means different things to youngsters, so sex ed ... THURSDAY, Aug. 21 (HealthDay News) -- One reason why ... activity is because abstinence can mean different things to ... University of Washington study. , Teens, attitudes and intentions ...
Cached Medicine News:Health News:Five Steps for Staying in Financial Control with Long-Term Disability 2Health News:Five Steps for Staying in Financial Control with Long-Term Disability 3Health News:Five Steps for Staying in Financial Control with Long-Term Disability 4Health News:CytoViva(R) Introduces Breakthrough Nano-Technology Research Tool 2Health News:Cleveland Clinic Launches Fully Dedicated International Comprehensive Critical Care Program 2Health News:Cleveland Clinic Launches Fully Dedicated International Comprehensive Critical Care Program 3Health News:Blue Shield of California CEO to Speak at Democratic Convention Host Committee's Health Roundtable in Denver 2Health News:Abstinence-Only Programs Fall Short of Teens' Needs 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: